VANI — Vivani Medical Inc.
NASDAQ · Healthcare · Biotechnology
$1.39
+$0.03 (+2.21%)
Vivani Medical Inc. (VANI) is a biotechnology company listed on NASDAQ. It is led by Adam Mendelsohn Ph.D., based in 1350 South Loop Road, Alameda, CA, United States, 94502, with about 42 employees. Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
Net income was -$6.5M. VANI currently screens at market cap $99.2M.
Use this VANI page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the VANI quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the VANI SEC filings page. Lician reads the product cache first so this HTML stays unique to Vivani Medical Inc. even when a live quote feed is slow.
About Vivani Medical Inc.
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
VANI Key Statistics
Market Cap
$99.17M
Volume
91,700
Previous Close
$1.38
Day Range
$1.34 – $1.40
P/B Ratio
5.20
EPS
-$0.43
Revenue
$0.00
Net Income
-$23.49M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
42
VANI Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$23.49M | -$25.65M | -$13.89M | -$1.28M |
| EPS (Diluted) | -$0.43 | -$0.50 | $0.00 | $0.00 |
Total Assets
$41.56M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$18.35M
Operating Cash Flow
-$20.79M
Free Cash Flow
$0.00
Vivani Medical Inc. Company Information
- Co-Founder, CEO & Director
- Adam Mendelsohn Ph.D.
- Headquarters
- 1350 South Loop Road, Alameda, CA, United States, 94502
- Website
- www.vivani.com
- Phone
- 415 506 8462
- IPO / Founded
- 2014-11-19
- Sector
- Healthcare
- Industry
- Biotechnology